Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotagliflozin - Lexicon Pharmaceuticals

X
Drug Profile

Sotagliflozin - Lexicon Pharmaceuticals

Alternative Names: INPEFA; LP-802034; LX-4211; SAR 439954; Zynquista

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; Sanofi
  • Class Alcohols; Antihyperglycaemics; Chlorobenzenes; Glycosides; Heart failure therapies; Phenyl ethers; Pyrans; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Type 2 diabetes mellitus
  • Registered Type 1 diabetes mellitus

Most Recent Events

  • 03 Jun 2024 Adverse events data from a phase III trial in Type II diabetes mellitus and Renal failure presented at the 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)
  • 02 May 2024 Lexicon plans a phase III trial for Hypertrophic cardiomyopathy and expects to begin enrollment in the middle of the year 2024
  • 29 Apr 2024 Lexicon Pharmaceuticals announces intention to launch sotagliflozin for hypertrophic cardiomyopathy by late 2027
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top